(Q44479748)

3 December 2017

title

The cost-effectiveness of a universal influenza vaccination program for adults aged 50-64 years in Australia (English)

1 reference

3 December 2017

0 references

2

1 reference

3 December 2017

Anthony T Newall

1

0 references

Raina MacIntyre

series ordinal

5

object named as

C Raina Macintyre

1 reference

3 December 2017

3

Heath Kelly

1 reference

3 December 2017

Stuart Harsley

4

1 reference

3 December 2017

language of work or name

English

0 references

publication date

20 February 2008

1 reference

3 December 2017

1 reference

3 December 2017

volume

26

1 reference

3 December 2017

issue

17

1 reference

3 December 2017

page(s)

2142-2153

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

3 December 2017

1 reference

Economic impact of providing workplace influenza vaccination. A model and case study application at a Brazilian pharma-chemical company

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

The cost-effectiveness of influenza vaccination for people aged 50 to 64 years: an international model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza vaccination health impact and cost effectiveness among adults aged 50 to 64 and 65 and older.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

The cost-effectiveness of influenza vaccination of healthy adults 50-64 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza-associated morbidity and mortality in young and middle-aged women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza-associated mortality in Hong Kong

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza-associated hospitalizations in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Mortality associated with influenza and respiratory syncytial virus in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Estimating influenza-related hospital admissions in older people from GP consultation data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

The impact of influenza epidemics on hospitalizations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Mortality due to influenza in the United States--an annualized regression approach using multiple-cause mortality data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza coverages in Spain and vaccination-related factors in the subgroup aged 50–64 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Antivirals for influenza in healthy adults: systematic review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Impact of zanamivir treatment on productivity, health status and healthcare resource use in patients with influenza. Zanamivir Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza burden of illness: estimates from a national prospective survey of household contacts in France.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Economic costs of influenza-related work absenteeism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

The impact of influenza and influenza-like illness on productivity and healthcare resource utilization in a working population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Estimating deaths due to influenza and respiratory syncytial virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Estimating deaths due to influenza and respiratory syncytial virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Impact of influenza vaccination on seasonal mortality in the US elderly population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Commentary: benefits of influenza vaccine in US elderly--new studies raise questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Evidence of bias in estimates of influenza vaccine effectiveness in seniors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Influenza vaccination: policy versus evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Inactivated influenza vaccines in the elderly—are you sure?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Mortality benefits of influenza vaccination in elderly people: an ongoing controversy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Systematic review and economic decision modelling for the prevention and treatment of influenza A and B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2008.01.050

10.1016/J.VACCINE.2008.01.050

7 January 2021

Identifiers

DOI

1 reference

3 December 2017

1 reference